-
1
-
-
0000869162
-
The mucopolysaccharidoses
-
C.R. Scriver, A.L. Beaudet, W.S. Sly, McGraw-Hill New York
-
E.F. Neufeld, and J. Muenzer The mucopolysaccharidoses C.R. Scriver, A.L. Beaudet, W.S. Sly, The metabolic and molecular basis of inherited disease 2001 McGraw-Hill New York 3421 3452
-
(2001)
The Metabolic and Molecular Basis of Inherited Disease
, pp. 3421-3452
-
-
Neufeld, E.F.1
Muenzer, J.2
-
2
-
-
59449083175
-
Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis i
-
L.A. Clarke, J.E. Wraith, and M. Beck Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I Pediatrics 123 2009 229 240
-
(2009)
Pediatrics
, vol.123
, pp. 229-240
-
-
Clarke, L.A.1
Wraith, J.E.2
Beck, M.3
-
3
-
-
57649092465
-
A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis i
-
R. Giugliani, V.M. Rojas, and A.M. Martins A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I Mol Genet Metab 96 2009 13 19
-
(2009)
Mol Genet Metab
, vol.96
, pp. 13-19
-
-
Giugliani, R.1
Rojas, V.M.2
Martins, A.M.3
-
4
-
-
0035905889
-
Enzyme-replacement therapy in mucopolysaccharidosis i
-
E.D. Kakkis, J. Muenzer, and G.E. Tiller Enzyme-replacement therapy in mucopolysaccharidosis I N Engl J Med 344 2001 182 188
-
(2001)
N Engl J Med
, vol.344
, pp. 182-188
-
-
Kakkis, E.D.1
Muenzer, J.2
Tiller, G.E.3
-
5
-
-
34447121276
-
Enzyme replacement therapy in patients who have mucopolysaccharidosis i and are younger than 5 years: Results of a multinational study of recombinant human alpha-l-iduronidase (laronidase)
-
J.E. Wraith, M. Beck, and R. Lane Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: Results of a multinational study of recombinant human alpha-l-iduronidase (laronidase) Pediatrics 120 2007 e37 e46
-
(2007)
Pediatrics
, vol.120
-
-
Wraith, J.E.1
Beck, M.2
Lane, R.3
-
6
-
-
2342666229
-
Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase)
-
J.E. Wraith, L.A. Clarke, and M. Beck Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase) J Pediatr 144 2004 581 588
-
(2004)
J Pediatr
, vol.144
, pp. 581-588
-
-
Wraith, J.E.1
Clarke, L.A.2
Beck, M.3
-
7
-
-
34547906935
-
Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome
-
J.A. Thomas, S. Jacobs, J. Kierstein, and J. Van Hove Outcome after three years of laronidase enzyme replacement therapy in a patient with Hurler syndrome J Inherit Metab Dis 29 2006 762
-
(2006)
J Inherit Metab Dis
, vol.29
, pp. 762
-
-
Thomas, J.A.1
Jacobs, S.2
Kierstein, J.3
Van Hove, J.4
-
8
-
-
33846407580
-
Restricted upper extremity range of motion in mucopolysaccharidosis type I: No response to one year of enzyme replacement therapy
-
J. Cox-Brinkman, M.J. Smeulders, C.E. Hollak, and F.A. Wijburg Restricted upper extremity range of motion in mucopolysaccharidosis type I: No response to one year of enzyme replacement therapy J Inherit Metab Dis 30 2007 47 50
-
(2007)
J Inherit Metab Dis
, vol.30
, pp. 47-50
-
-
Cox-Brinkman, J.1
Smeulders, M.J.2
Hollak, C.E.3
Wijburg, F.A.4
-
9
-
-
77953232381
-
Efficacy of recombinant human alpha-l-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type i patients
-
A. Tylki-Szymanska, J. Marucha, A. Jurecka, M. Syczewska, and B. Czartoryska Efficacy of recombinant human alpha-l-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients J Inherit Metab Dis 33 2010 151 157
-
(2010)
J Inherit Metab Dis
, vol.33
, pp. 151-157
-
-
Tylki-Szymanska, A.1
Marucha, J.2
Jurecka, A.3
Syczewska, M.4
Czartoryska, B.5
-
10
-
-
33846198829
-
A follow-up study of MPS i patients treated with laronidase enzyme replacement therapy for 6 years
-
M. Sifuentes, R. Doroshow, and R. Hoft A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years Mol Genet Metab 90 2007 171 180
-
(2007)
Mol Genet Metab
, vol.90
, pp. 171-180
-
-
Sifuentes, M.1
Doroshow, R.2
Hoft, R.3
-
11
-
-
77956502514
-
Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS i patients
-
G.V. Coppa, D. Buzzega, and L. Zampini Effect of 6 years of enzyme replacement therapy on plasma and urine glycosaminoglycans in attenuated MPS I patients Glycobiology 20 2010 1259 1273
-
(2010)
Glycobiology
, vol.20
, pp. 1259-1273
-
-
Coppa, G.V.1
Buzzega, D.2
Zampini, L.3
-
12
-
-
84881016898
-
Scheie syndrome: Enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression
-
(Epub ahead of print)
-
S. Illsinger, T. Lucke, and H. Hartmann Scheie syndrome: Enzyme replacement therapy does not prevent progression of cervical myelopathy due to spinal cord compression J Inherit Metab Dis 2009 Nov 4 (Epub ahead of print)
-
(2009)
J Inherit Metab Dis
-
-
Illsinger, S.1
Lucke, T.2
Hartmann, H.3
-
13
-
-
59449100963
-
Mucopolysaccharidosis I: Management and treatment guidelines
-
J. Muenzer, J.E. Wraith, and L.A. Clarke Mucopolysaccharidosis I: Management and treatment guidelines Pediatrics 123 2009 19 29
-
(2009)
Pediatrics
, vol.123
, pp. 19-29
-
-
Muenzer, J.1
Wraith, J.E.2
Clarke, L.A.3
-
14
-
-
71649093573
-
Anthropometric data of 14 patients with mucopolysaccharidosis I: Retrospective analysis and efficacy of recombinant human alpha-l-iduronidase (laronidase)
-
A. Tylki-Szymanska, A. Rozdzynska, A. Jurecka, J. Marucha, and B. Czartoryska Anthropometric data of 14 patients with mucopolysaccharidosis I: Retrospective analysis and efficacy of recombinant human alpha-l-iduronidase (laronidase) Mol Genet Metab 99 2010 10 17
-
(2010)
Mol Genet Metab
, vol.99
, pp. 10-17
-
-
Tylki-Szymanska, A.1
Rozdzynska, A.2
Jurecka, A.3
Marucha, J.4
Czartoryska, B.5
-
15
-
-
79959785835
-
Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: The relevance of clinical trial end points
-
E. Glamuzina, E. Fettes, and K. Bainbridge Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: The relevance of clinical trial end points J Inherit Metab Dis 34 2011 749 754
-
(2011)
J Inherit Metab Dis
, vol.34
, pp. 749-754
-
-
Glamuzina, E.1
Fettes, E.2
Bainbridge, K.3
-
16
-
-
74049159044
-
Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up
-
O. Gabrielli, L.A. Clarke, S. Bruni, and G.V. Coppa Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up Pediatrics 125 2010 e183 e187
-
(2010)
Pediatrics
, vol.125
-
-
Gabrielli, O.1
Clarke, L.A.2
Bruni, S.3
Coppa, G.V.4
|